The process of atherosclerotic plaque destabilization, leading to myocardial infarction, is still not fully understood. The pathway -composed of structural and regulatory proteins of the extracellular matrix (ECM) such as collagen, elastin, small leucine-rich proteoglycans, metalloproteinases, cathepsins and serine proteases -is one potential way of atherosclerotic plaque destabilization. The expression of these proteins is controlled by different microRNA molecules. The goal of this paper is to summarize the current investigations and knowledge about ECM in the process of atherosclerotic plaque destabilization, giving special attention to epigenetic expression regulation by microRNA.
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| INTRODUCTION
The main cause of death worldwide are diseases related to atherosclerotic plaque, for instance, acute coronary syndrome (including myocardial infarction). Acute coronary syndrome is a consequence of vulnerable atherosclerotic plaque rupture. 1 The vulnerable plaque is composed of a thin fibrous cap, fragmented extracellular matrix (ECM) fibres, necrotic fields and inflammatory cells, in contrast to stable plaque (Table 1) .
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Its rupture, caused by an increase of local hemodynamic forces, leads to ECM exposition to the blood stream. 3, 4 Next, a thrombus is generated upon the exposed area of the plaque, which occludes or even obstructs the culprit coronary artery and causes necrosis of the corresponding myocardial muscle region, i.e., myocardial infarction. 5 It is considered that a stable atherosclerotic plaque can transform into a vulnerable one in a process called destabilization of the plaque. 6 Many different factors contribute to this process, including immune system cytokinetic regulation, 7 
| EXTRACELLULAR MATRIX
Extracellular matrix constitutes atherosclerotic plaque scaffolding, in which different cells and cellular structures are suspended. It is built up with structural elements, which are regulated by different proteins.
The regulation of ECM guides the atherosclerotic plaque toward stabilization or destabilization. Structural ECM elements and its regulatory factors are described in Figure 2 .
| Extracellular matrix -structural elements

| Collagen
Collagen is a family of fibrous proteins, components of the ECM, that stabilize the plaque. 16 Collagen fibres are composed of three alpha chains coiling around each other. Sequence differences between the chains determine the integral structure and type of collagen. ECM within the pIaque contains mainly collagen type I and III, albeit other types of collagen (IV, V, VI and VIII) are also found. with a thin fibrous cap in contrast to single knockout ApoE (−/−) animals, which has been described by Lopes et al. 24 However, collagen (especially collagen type I) decreases arterial elasticity. In ApoE (−/−) mice, the level of miR-145 is reduced, so that the expression of the lysyl oxidase gene (LOX) is increased. Lysyl oxidase crosslinks collagen helices and strengthens collagen fibres, which increase the arterial stiffness in these mice. 
| Elastin
Elastin is an ECM protein responsible for arterial vessel elasticity, preventing arterial stiffness. It is an amorphic and hydrophobic polymer composed of extensively crosslinked fibres. The relationship between elastin and its degradative enzymes, elastases, has been mentioned in reference to aging and atherosclerosis. 
The microRNA activity and biogenesis
The ECM structural elements and its regulatory factors have revealed, that antagomir-29b significantly reduces aortic aneurysm diameter in ApoE (−/−) mice, whereas the miR-195 serum level correlates with the aortic aneurysm diameter in patients. Surprisingly, this is an inverse correlation, because miR-195 inhibits not only elastin and collagens, but also metalloproteinase MMP-9, which is an enzyme degrading ECM. 28 The matrix metalloproteinases are discussed widely in the following sections of this manuscript. Apart from that, the molecule miR-181b is another epigenetic regulator of the elastin gene expression. 29 Its inhibition by anti-miR-181b resulted in the attenuation of aortic aneurysm development and an increase of fibrotic response and stabilization of atherosclerotic plaques or aneurysms in ApoE (−/−) mice.
| Proteoglycans
This is a family of highly glycosylated proteins, in which glycosaminoglycan chains are attached to the protein core. There are small and large molecules among proteoglycans. In the ECM, small proteoglycan molecules called small leucine-rich proteins (SLRPs) are of particular importance. They are divided into two classes: class I SLRP, biglycan and decorin (chondroitin sulfate and dermatan sulfate proteoglycans);
and class II SLRP, lumican, fibromodulin and prolargin/proline argininerich end leucine-rich repeat protein (PRELP). 30 Firstly, SLRPs regulate and maintain the architecture of collagen fibres by binding to them via leucine-rich domain. 31 For instance, in decorin knockout mice, collagen fibres have a different size. 32 Secondly, they regulate different molecular processes within the plaque, including destabilization.
Lumican binds proinflammatory CXCL1 cytokine, providing a cytokine gradient for leukocyte migration, thus regulating chemotaxis. In addition, lumican increases phagocytosis within the plaque by interaction with CD14. 33, 34 Decorin is a proinflammatory proteoglycan that promotes TLR2 and TLR4 downstream induction and decreases ECM synthesis. 35 In addition, TLR2 and TLR4 mediated inflammatory cytokine production is regulated also by biglycan. 36 Both of these SLRPs are responsible for lipid retention within the atherosclerotic plaque, because they bind low density lipoprotein (LDL) particles by electrostatic interactions. 37 As a consequence, transgenic mice expressing human biglycan presented increased atherosclerotic plaque burden and lipid retention within the plaque compared with wild type mice, which has been shown by Tannock et al. 38 Lastly, fibromodulin binds to C1q complement element and, contrary to the other aforementioned SLRPs, activates the complement by the classical pathway, which contributes to the regulation of the inflammatory processes. 39 SLRPs in the atherosclerotic plaque have been widely described by
Hultghard-Nisson et al. 40 Decorin is a proteoglycan most widely discussed in reference to microRNA involvement. Its expression is under negative control of miR-181b, which has been demonstrated by an investigation into hypertrophic scars. 41 Decorin also promotes proinflammatory macrophage activation via PDCD4 (programmed cell death 4) and negatively regulates miR-21 expression. Because miR-21 is considered to be an oncogene (oncomir), decorin seems to suppress cancer growth. 42 ECM of the atherosclerotic plaque is also composed of hyaluronic acid, which is a polysaccharide containing a long glycosaminoglycan chain. It is supposed to enhance plaque stability. 43 Yet, increased turnover of hyaluronic acid by interaction with CD44 as well as hyaluronidase activity generates an increased amount of proinflammatory LMW-HA (low molecular weight hyaluronic acid) particles that destabilize the atherosclerotic plaque. 44 It is hypothesized, however, that hyaluronic acid promotes miR-10 expression. The miR-10, by direct modulation of fms-related tyrosine kinase-1 (flt-1) and Mib-1, induces blood vessel growth. 45, 46 Importantly, neovascularization is a marker of atherosclerotic plaque destabilization. The hyaluronic acid and its receptor, CD44, generally promotes tumor progression.
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For example, it induces the aforementioned oncomir miR21 by activation of the c-Jun signaling pathway. 48 Therefore, the role of hyaluronic acid in atherosclerotic plaque destabilization needs to be further clarified, as well as its regulation by microRNA molecules. For instance, CD44, a receptor for hyaluronic acid, is inhibited by miR-328, which has been demonstrated in renal tubular cells. 49 It is worth mentioning, that proteoglycan expression could also be regulated together with collagen expression by miR-599. 
| Other structural ECM components
Apart from the aforementioned structural elements, the ECM has other components that are able to affect its integrity and function.
Fibronectin, discovered as fibroblast cell surface glycoprotein, constitutes a provisional ECM network surrounding the cells and regulates collagen fibre assembly. 51 One of its spliced variants, extra domain A (EDA), stabilizes the atherosclerotic plaque. 52 Finally, thrombospondin-5 or cartilage oligomeric matrix protein (COMP) is a protein that forms a star-like structure within the ECM and facilitates collagen fibril formation. 53 All the ECM components make up a highly advanced network, which constitutes the scaffolding of the atherosclerotic plaque structure and their role in plaque stability should not be underestimated. also plays a role in atherosclerotic plaque destabilization. The former is a stabilizing agent, whereas the latter is a destabilizing one. Therefore, Newby's hypothesis that plaque rupture is associated with "a storm of metalloproteinase activation" seems reasonable. It is worth noting that cathepsin S causes elastin degradation with the generation of biologically active and proinflammatory EDP (as mentioned above). 83 Cathepsin K promotes collagen type I degradation, which has been demonstrated on in vitro macrophage cell lines. ). This surprising result can be explained by epigenetic alteration, i.e., cathepsin K-deficient macrophages accumulate more F I G U R E 3 Plaque destabilization microRNA network -focus on metalloproteinases cholesterol esters because of increased CD36 expression. 86 In contrast, ApoE (−/−) double knockout mice with cathepsin K-deficiency, i.e., ApoE (−/−) CatK (−/−) mice, present a more stable plaque phenotype. 87 In our opinion, these differences might also be a consequence of different epigenetic regulations in ApoE (−/−) and LDLR (−/−) mice.
| Extracellular matrix -regulatory elements
| Metalloproteinases
Cathepsin L and B are related to increased atherosclerotic plaque vulnerability, which has been observed in human carotid atherosclerotic lesion specimens. 88, 89 The cystatin C serum level has been shown to be positively correlated with atherosclerotic burden and lesion stability in patients undergoing coronary angiography. 90 Thus, cystatin C is considered to be an agent preventing atherosclerotic plaque from destabilization. 91 The expression of cathepsins is also under the control of microRNA molecules. Nevertheless, few investigations have been undertaken in this matter, except for cystatin C. In a study on 199 consecutive patients with lower limb ischemia and diabetes type 2, it has been shown that miR-92a decreases cystatin C expression and is more abundant in limb-ischemic patients. 
| Serine proteases
| CONCLUSION
Atherosclerotic plaque destabilization is a complex process related also to ECM. The role of matrix structural and regulatory elements in this process has been investigated widely, although a lot of important information is still missing. Agents stabilizing and destabilizing the plaque have been presented in Figure 4 . Additionally, 
